Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 56

1.

Current Landscape and the Potential Role of Hypoxia-Inducible Factors and Selenium in Clear Cell Renal Cell Carcinoma Treatment.

Garje R, An JJ, Sanchez K, Greco A, Stolwijk J, Devor E, Rustum Y, Zakharia Y.

Int J Mol Sci. 2018 Dec 1;19(12). pii: E3834. doi: 10.3390/ijms19123834. Review.

2.
3.

Selenium targets resistance biomarkers enhancing efficacy while reducing toxicity of anti-cancer drugs: preclinical and clinical development.

Zakharia Y, Bhattacharya A, Rustum YM.

Oncotarget. 2018 Jan 23;9(12):10765-10783. doi: 10.18632/oncotarget.24297. eCollection 2018 Feb 13. Review.

4.

Enrico Mihich, MD: In Memoriam (1928-2016).

Foti M, Rustum YM.

Cancer Res. 2017 Jul 1;77(13):3383-3385. doi: 10.1158/0008-5472.CAN-17-1723. No abstract available.

5.

Randomized phase II trial of selenomethionine as a modulator of efficacy and toxicity of chemoradiation in squamous cell carcinoma of the head and neck.

Mix M, Singh AK, Tills M, Dibaj S, Groman A, Jaggernauth W, Rustum Y, Jameson MB.

World J Clin Oncol. 2015 Oct 10;6(5):166-73. doi: 10.5306/wjco.v6.i5.166.

6.

Effects of selenomethionine on acute toxicities from concurrent chemoradiation for inoperable stage III non-small cell lung cancer.

Mix M, Ramnath N, Gomez J, de Groot C, Rajan S, Dibaj S, Tan W, Rustum Y, Jameson MB, Singh AK.

World J Clin Oncol. 2015 Oct 10;6(5):156-65. doi: 10.5306/wjco.v6.i5.156.

7.

Investigation of hydrophobically derivatized hyperbranched polyglycerol with PEGylated shell as a nanocarrier for systemic delivery of chemotherapeutics.

Misri R, Wong NK, Shenoi RA, Lum CM, Chafeeva I, Toth K, Rustum Y, Kizhakkedathu JN, Khan MK.

Nanomedicine. 2015 Oct;11(7):1785-95. doi: 10.1016/j.nano.2015.04.016. Epub 2015 May 14.

PMID:
25981338
8.

Constitutive expression of HIF-α plays a major role in generation of clear-cell phenotype in human primary and metastatic renal carcinoma.

Tóth K, Chintala S, Rustum YM.

Appl Immunohistochem Mol Morphol. 2014 Oct;22(9):642-7. doi: 10.1097/PAI.0000000000000012.

9.

MicroRNA-627 mediates the epigenetic mechanisms of vitamin D to suppress proliferation of human colorectal cancer cells and growth of xenograft tumors in mice.

Padi SK, Zhang Q, Rustum YM, Morrison C, Guo B.

Gastroenterology. 2013 Aug;145(2):437-46. doi: 10.1053/j.gastro.2013.04.012. Epub 2013 Apr 22.

10.

A novel small molecule FL118 that selectively inhibits survivin, Mcl-1, XIAP and cIAP2 in a p53-independent manner, shows superior antitumor activity.

Ling X, Cao S, Cheng Q, Keefe JT, Rustum YM, Li F.

PLoS One. 2012;7(9):e45571. doi: 10.1371/journal.pone.0045571. Epub 2012 Sep 19.

11.
12.

In vivo toxicity evaluation of gold-dendrimer composite nanodevices with different surface charges.

Kasturirangan V, Nair BM, Kariapper MT, Lesniak WG, Tan W, Bizimungu R, Kanter P, Toth K, Buitrago S, Rustum YM, Hutson A, Balogh LP, Khan MK.

Nanotoxicology. 2013 Jun;7(4):441-51. doi: 10.3109/17435390.2012.668570. Epub 2012 Mar 20.

PMID:
22394369
13.

Selenium is a modulator of circadian clock that protects mice from the toxicity of a chemotherapeutic drug via upregulation of the core clock protein, BMAL1.

Hu Y, Spengler ML, Kuropatwinski KK, Comas-Soberats M, Jackson M, Chernov MV, Gleiberman AS, Fedtsova N, Rustum YM, Gudkov AV, Antoch MP.

Oncotarget. 2011 Dec;2(12):1279-90.

14.

Ugt1a is required for the protective effect of selenium against irinotecan-induced toxicity.

Cao S, Durrani FA, Rustum YM, Yu YE.

Cancer Chemother Pharmacol. 2012 Apr;69(4):1107-11. doi: 10.1007/s00280-011-1820-8. Epub 2012 Jan 12.

15.

Augmented therapeutic efficacy of irinotecan is associated with enhanced drug accumulation.

Azrak RG, Cao S, Durrani FA, Toth K, Bhattacharya A, Rustum YM.

Cancer Lett. 2011 Dec 8;311(2):219-29. doi: 10.1016/j.canlet.2011.07.023. Epub 2011 Aug 6.

16.

Bevacizumab enhances the therapeutic efficacy of Irinotecan against human head and neck squamous cell carcinoma xenografts.

Cao S, Durrani FA, Toth K, Rustum YM, Seshadri M.

Oral Oncol. 2011 Jun;47(6):459-66. doi: 10.1016/j.oraloncology.2011.04.001. Epub 2011 May 6.

17.

Magnetic resonance and fluorescence-protein imaging of the anti-angiogenic and anti-tumor efficacy of selenium in an orthotopic model of human colon cancer.

Bhattacharya A, Turowski SG, San Martin ID, Rajput A, Rustum YM, Hoffman RM, Seshadri M.

Anticancer Res. 2011 Feb;31(2):387-93.

18.

Targeting the oncogenic protein beta-catenin to enhance chemotherapy outcome against solid human cancers.

Saifo MS, Rempinski DR Jr, Rustum YM, Azrak RG.

Mol Cancer. 2010 Dec 2;9:310. doi: 10.1186/1476-4598-9-310.

19.

Downregulation of cystine transporter xc by irinotecan in human head and neck cancer FaDu xenografts.

Chintala S, Tóth K, Yin MB, Bhattacharya A, Smith SB, Ola MS, Cao S, Durrani FA, Zinia TR, Dean R, Slocum HK, Rustum YM.

Chemotherapy. 2010;56(3):223-33. doi: 10.1159/000316334. Epub 2010 Jun 11.

20.

Architectural heterogeneity in tumors caused by differentiation alters intratumoral drug distribution and affects therapeutic synergy of antiangiogenic organoselenium compound.

Rustum YM, Tóth K, Seshadri M, Sen A, Durrani FA, Stott E, Morrison CD, Cao S, Bhattacharya A.

J Oncol. 2010;2010:396286. doi: 10.1155/2010/396286. Epub 2010 Apr 27.

Supplemental Content

Loading ...
Support Center